𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Nilotinib in the Post-Imatinib Era for the Treatment of Philadelphia Chromosome–Positive Leukemias

✍ Scribed by Mughal, Tariq I.

Book ID
122629622
Publisher
CIG Media Group, LP.
Year
2006
Tongue
English
Weight
85 KB
Volume
1
Category
Article
ISSN
1931-6925

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Expanding Nilotinib Access in Clinical T
Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase
✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH